Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015

Press/Media: Press / Media

PeriodMay 30 2015 → May 31 2015

Media coverage

33

Media coverage

  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletRed Orbit
    CountryUnited States
    Date5/31/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletBloomberg
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletIndividual.com
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletTown Hall
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletMarketplace
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletBioSpace
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletRCL Advisors
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletA.M. Best
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletVision Monday
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletNasdaq
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletSecurities Technology Monitor
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletStockwatch
    CountryCanada
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In..
    Media name/outletADVFN India
    CountryIndia
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletTamar Securities
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletTickerTech.com
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletBarchart
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitleCTI BIOPHARMA : Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outlet4 Traders
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletTutorial Finder
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletReview Seeker
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletUSA Life Sciences Database
    CountrySwitzerland
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletFinancial Content
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletBiotechgate
    CountrySwitzerland
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletAsian Hospital & Healthcare Management
    CountryIndia
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletPipelineReview
    CountrySpain
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletPharmacy Choice
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletAsk.com
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletU-T San Diego
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletIndianapolis Business Journal
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletMichigan Live
    CountryUnited States
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletNoodls
    CountryItaly
    Date5/30/15
    PersonsRuben Mesa
  • TitlePhase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
    Media name/outletStockhouse Bulletin Boards
    CountryCanada
    Date5/30/15
    PersonsRuben Mesa